期刊
DIABETES OBESITY & METABOLISM
卷 20, 期 2, 页码 257-269出版社
WILEY
DOI: 10.1111/dom.13062
关键词
GPR119; metabolic diseases; non-alcoholic fatty liver disease; physiological; pharmacological effects; synthetic ligands; type 2 diabetes mellitus
资金
- National Research Foundation of Korea (NRF)
- Korean Government [2017M3A9C8028794, 2015M3A9B6053068]
- National Research Foundation of Korea [2015M3A9B6053068] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
GPR119 belongs to the G protein-coupled receptor family and exhibits dual modes of action upon ligand-dependent activation: pancreatic secretion of insulin in a glucose-dependent manner and intestinal secretion of incretins. Hence, GPR119 has emerged as a promising target for treating type 2 diabetes mellitus without causing hypoglycaemia. However, despite continuous efforts by many major pharmaceutical companies, no synthetic GPR119 ligand has been approved as a new class of anti-diabetic agents thus far, nor has any passed beyond phase II clinical studies. Herein, we summarize recent advances in research concerning the physiological/pharmacological effects of GPR119 and its synthetic ligands on the regulation of energy metabolism, and we speculate on future applications of GPR119 ligands for the treatment of metabolic diseases, focusing on non-alcoholic fatty liver disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据